Project description DEENESFRITPL Application of bioengineered resveratrol in new anticancer therapy concepts Resveratrol is a natural polyphenol of plant origin that acts against pathogens, including bacteria and fungi. Funded by the Marie Skłodowska-Curie Actions programme, the p53-REACT project aims to engineer a bacterial host to produce resveratrol metabolite variants and study their interaction with the tumour suppressor protein p53. The objective is to elucidate the mode of action of resveratrol molecules on the p53 mutants with a focus on new concepts for cancer therapy. The project represents a broad study of the resveratrol derivatives acting as p53 aggregation inhibitors and involves cutting-edge computational resources and metabolic and structural bioengineering. Show the project objective Hide the project objective Objective The project proposal aims to engineer a bacterial host to produce variants of secondary metabolite resveratrol and address the interrelationship between dynamics, structure and function of a system of high medical interest, the tumor suppressor protein p53. The study considers to elucidate the mode of action of these molecules against the p53 mutants and work on new concepts for cancer therapy. Inside the cell, the folding of a protein is a fast and robust process. Sometimes, however, sudden changes in the balance between different existing forces result in incorrect folding of the peptide chain, which ends up generating amyloid aggregates within the cell that lead to the gain of toxic function, since these aggregates can conduct to death of the cell in question. Most amyloidogenic pathologies are neurodegenerative, however the aggregation also plays an important role in cancer. The project provides a broad framework for the study of the resveratrol derivatives acting as p53 aggregation inhibitors by using cutting-edge tools of computational resources, metabolic engineering and structural biology. But could, in principal, be applied to exploit the chemical diversity of other biocompounds similarly intending to act as less cytotoxic agents in a more effective antineoplastic therapy, which represents one of the major existing scientific gaps. It is a proposal on a very important topic that will be studied from a unique perspective. Fields of science engineering and technologyindustrial biotechnologymetabolic engineeringnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicineoncologymedical and health sciencesbasic medicinepathologynatural sciencesbiological sciencesmolecular biologystructural biology Programme(s) HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme Topic(s) HORIZON-MSCA-2021-PF-01-01 - MSCA Postdoctoral Fellowships 2021 Call for proposal HORIZON-MSCA-2021-PF-01 See other projects for this call Funding Scheme HORIZON-AG-UN - HORIZON Unit Grant Coordinator TECHNISCHE UNIVERSITAET MUENCHEN Net EU contribution € 189 687,36 Address Arcisstrasse 21 80333 Muenchen Germany See on map Region Bayern Oberbayern München, Kreisfreie Stadt Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window EU contribution No data Partners (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all Rensselaer Polytechnic Institute United States Net EU contribution € 0,00 Address 8th street 110 12180 Troy See on map Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding No data
